For decades, B cells were ignored in multiple sclerosis (MS) pathogenesis, and the disease
was always regarded as a T cell‐mediated disorder. Recent evidence shows that there is an …

Multiple sclerosis (MS) is considered to be a T cell-mediated autoimmune disease that
results in the presence of inflammatory lesions/plaques associated with mononuclear cell …

Epstein–Barr virus (EBV) is an aetiologic risk factor for the development of multiple sclerosis
(MS). However, the role of EBV-infected B cells in the immunopathology of MS is not well …

The past few years have provided insights into the multiple paths by which innate immune
signals can lead to B cell activation in SLE and pSS and the increasingly diverse ways in …

B cells play a central role in multiple sclerosis (MS) pathology. B and plasma cells may
contribute to disease activity through multiple mechanisms: antigen presentation, cytokine …

Multiple sclerosis is a common neurological disorder that represents a significant source of
disability. B cells have recently emerged as a novel therapeutic target for multiple sclerosis …

The success of ocrelizumab in reducing confirmed disability accumulation in primary
progressive multiple sclerosis (PPMS) via CD20-targeted depletion implicates B cells as …

Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous
system. Once thought to be primarily driven by T cells, B cells are emerging as central …

Multiple sclerosis is a chronic debilitating autoimmune disease of the central nervous
system. The contribution of B cells in the pathoetiology of MS has recently been highlighted …

Objective B cell targeted therapies have been effective in slowing multiple sclerosis (MS)
disease progression suggesting a direct causal link for this lymphoid subset. A small subset …